{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:19:49Z","timestamp":1783088389213,"version":"3.54.6"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159202"],"award-info":[{"award-number":["92159202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470230"],"award-info":[{"award-number":["82470230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["CXLJ202401"],"award-info":[{"award-number":["CXLJ202401"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key R&D Plan in Zhejiang Province","doi-asserted-by":"publisher","award":["2024C03051"],"award-info":[{"award-number":["2024C03051"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.canlet.2026.218593","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:30:44Z","timestamp":1779147044000},"page":"218593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["USP22 inhibition potentiates GPC3 chimeric antigen receptor macrophages efficacy in hepatocellular carcinoma by downregulating tumor CD24 expression"],"prefix":"10.1016","volume":"655","author":[{"given":"Jun","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunguo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunbin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218593_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218593_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218593_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218593_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.21147\/j.issn.1000-9604.2023.02.02","article-title":"When immunotherapy meets liver transplantation for hepatocellular carcinoma: a bumpy but promising road","volume":"35","author":"Gu","year":"2023","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218593_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.hbpd.2024.10.004","article-title":"No-touch recipient hepatectomy in liver transplantation for liver malignancies: a state-of-the-art review","volume":"24","author":"Xu","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.canlet.2026.218593_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218593_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.32604\/or.2024.047524","article-title":"CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression","volume":"32","author":"Yi","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2026.218593_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152434","article-title":"Nanoparticle-based approaches for doxorubicin delivery in hepatocellular carcinoma: current strategies and emerging innovations","volume":"53","author":"Alkhathami","year":"2026","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2026.218593_bib9","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218593_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK cells in the treatment of solid tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218593_bib11","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218593_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121917","article-title":"Theranostic chimeric antigen receptor (CAR)-T cells: insight into recent trends and challenges in solid tumors","volume":"328","author":"Kheyrolahzadeh","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2026.218593_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218593_bib14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/d41573-020-00053-9","article-title":"Macrophages get a CAR","volume":"19","author":"Villanueva","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218593_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103873","article-title":"CAR-macrophage: an extensive immune enhancer to fight cancer","volume":"76","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218593_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218593_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091339","article-title":"Glypican 3-Targeted therapy in hepatocellular carcinoma","volume":"11","author":"Nishida","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218593_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.canlet.2026.218593_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218593_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcis.2026.139927","article-title":"Glutathione- responsive phototheranostic platform for imaging-guided enhanced oxidation photoimmunotherapy-ferroptosis synergistic hepatocellular carcinoma therapy","volume":"709","author":"He","year":"2026","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.canlet.2026.218593_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-Specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218593_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.122.265171","article-title":"Site-Specifically conjugated single-domain antibody successfully identifies Glypican-3-Expressing liver cancer by Immuno-PET","volume":"64","author":"Fayn","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218593_bib23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218593_bib24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide binder to Glypican-3 as a Theranostic agent for hepatocellular carcinoma","volume":"65","author":"Lin","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218593_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20507","article-title":"Don't eat me\/eat me signals as a novel strategy in cancer immunotherapy","volume":"9","author":"Khalaji","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.canlet.2026.218593_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218593_bib27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218593_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12081235","article-title":"CD24: a novel target for cancer immunotherapy","volume":"12","author":"Panagiotou","year":"2022","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.canlet.2026.218593_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.molcel.2012.03.024","article-title":"USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development","volume":"46","author":"Lin","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218593_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9120167","article-title":"Ubiquitin specific peptidase 22 regulates Histone H2B Mono-Ubiquitination and exhibits both oncogenic and tumor suppressor roles in cancer","volume":"9","author":"Jeusset","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218593_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-024-01963-5","article-title":"The p-MYH9\/USP22\/HIF-1alpha axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma","volume":"9","author":"Shan","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218593_bib32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gutjnl-2019-319616","article-title":"USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1alpha\/USP22 positive feedback loop upon TP53 inactivation","volume":"69","author":"Ling","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218593_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218593_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo4116","article-title":"A deubiquitination module essential for T(reg) fitness in the tumor microenvironment","volume":"8","author":"Montauti","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218593_bib35","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218593_bib36","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218593_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218593_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.canlet.2026.218593_bib39","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218593_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218593_bib41","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRPalpha immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218593_bib42","article-title":"Self-Activated cascade-responsive sorafenib and USP22 shRNA Co-Delivery System for synergetic hepatocellular carcinoma therapy","volume":"8","author":"Xu","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218593_bib43","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218593_bib44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:22:41Z","timestamp":1783084961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526003563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S0304383526003563"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218593","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"USP22 inhibition potentiates GPC3 chimeric antigen receptor macrophages efficacy in hepatocellular carcinoma by downregulating tumor CD24 expression","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218593"}}